Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly

A

Astavita

Status

Completed

Conditions

Sarcopenia

Treatments

Other: Astaxanthin formulation
Other: Exercise training
Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03368872
Ax sarcopenia study

Details and patient eligibility

About

The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial and skeletal muscle function in elderly subjects with evidence of mitochondrial dysfunction/sarcopenia.

Enrollment

41 patients

Sex

All

Ages

65 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Able to travel to and from the study facilities
  • Informed consent obtained

Exclusion criteria

  • Have significant disease(s) or condition(s) which, in the opinion of the investigator, may put the subject at risk because of their participation in the trial or may influence either the results of the trial or the subject's ability to participate in the trial
  • Hospitalization within 3 months for major atherosclerotic events (defined as combined incidence of myocardial infarction, urgent target-vessel revascularization, coronary bypass surgery and stroke) and for any hospitalization within 2 months.
  • Have any metal implant in the right upper limb, including metal stents, titanium pins/markers, etc.
  • Have an implanted cardiac pacemaker or other implanted cardiac device
  • Chronic, uncontrolled hypertension as judged by the Investigator (ie, Baseline SBP >150 mm Hg, DBP >90 mm Hg) or a SBP > 150 mm Hg or DBP > 95 mm Hg at the time of screening or baseline. If the initial BP reading is above these values, the reading may be repeated one time within 20 minutes of the initial reading.
  • Body mass index <18 or >32 kg/m2
  • Creatinine clearance calculated by the Cr/G method calculated to be <45 mL/min
  • Additional laboratory abnormalities determined as clinically significant by the Investigator Clinically significant abnormalities on physical examination (as judged by the Investigator)
  • History or evidence of renal, hepatic, pulmonary (including chronic asthma), endocrine (eg, diabetes, hypo- and hyperthyroidism, adrenal insufficiency), central nervous or neurologic disorders (MS, epilepsy, history of seisures), or gastrointestinal (cirrhosis or viral hepatitis) system dysfunction
  • History of seizures or epilepsy
  • History of serious mental illness as judged by the Investigator
  • Oral temperature >37.5°C at the time of the physical
  • Suspicion, or recent history, of alcohol or substance abuse or tobacco use, including positive results from the laboratory screening panels conducted at screening
  • Donated blood or blood products within the past 30 days
  • Subjects who in the opinion of the Investigator have a clinically significant abnormal 12-lead ECG during the screening period. Presence of atrial fibrillation, varying degrees of AV block, existence of a left bundle branch block, or evidence of previous myocardial infarction.
  • Subjects who are either unwilling to agree to refrain from using or found to be using supplementary antioxidant vitamins (eg, Coenzyme Q10) from 7 days prior to dosing and throughout the confinement period
  • Are currently enrolled in a clinical trial involving an investigational product or non approved use of a drug or device or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study Have participated, within the last 30 days from a clinical trial involving an investigational product. If the previous investigational product has a long half life, 3 months or 5 half-lives (whichever is longer) should have passed

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

41 participants in 2 patient groups, including a placebo group

Astaxanthin and exercise
Experimental group
Description:
Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
Treatment:
Other: Exercise training
Other: Astaxanthin formulation
Placebo and exercise
Placebo Comparator group
Description:
Placebo intake for one month followed by 3-month exercise training with placebo intake.
Treatment:
Other: Placebo
Other: Exercise training

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems